Swelling without hives: what the pattern can mean

Compare, then verify

Important alternatives clinicians keep open

These categories can look similar at first. The comparison is a reasoning map, not a self-triage test.

What happens next

How the clinical question may be worked through

For a stable person after any emergency has been addressed, a specialist workup may follow this sequence.

1. 1

   Protect the airway first

   Classifying the mechanism must never delay emergency assessment or airway management. A person with a confirmed action plan should follow it and still seek emergency assessment for suspected upper-airway swelling.^[1][2][3]

2. 2

   Reconstruct the attacks

   Document where swelling occurred, whether wheals or itching were present, abdominal episodes, voice or swallowing changes, duration, possible triggers, medicine exposure, response to prior treatment, and similar attacks in relatives.^[1][2]

3. 3

   Interpret complement testing as a set

   Use validated assays and interpret C1-inhibitor function, antigen, and C4 together. Repeat unreliable, abnormal, or clinically discordant findings rather than treating one number as final.^[1][2]

4. 4

   Pursue the branch the history supports

   When results or age of onset raise an acquired process, specialists may assess C1q, C1-inhibitor antibodies, and associated conditions. Normal C1-inhibitor studies can lead to a different hereditary, medicine, mast-cell, or unclassified pathway.^[1][2]

Plain-language answers

Questions this pattern often raises

Evidence trail

Sources, strengths, and limits

These are the same sources used for the linked constructed teaching case. They support the pattern and its boundaries; they do not turn this page into advice for an individual.

1. 1

   World Allergy Organization: 2025 Hereditary Angioedema Guideline

   What it supports: Supports treating recurrent non-urticarial skin, abdominal, or laryngeal swelling as a clue rather than confirmation; using C1-inhibitor functional activity as the preferred initial test only when an accurate, validated specialist laboratory is available; repeating unreliable or discordant results; distinguishing C1-inhibitor-deficient HAE from HAE with normal C1 inhibitor, acquired C1-inhibitor deficiency, medicine-associated angioedema, and mast-cell-mediated disease; and giving prescribed on-demand treatment plus seeking immediate emergency care when upper-airway swelling is suspected.

   Important limit: This WAO-funded document is titled the 2025 guideline but was accepted and collected in 2026 after searches through June 2025. Forty experts selected through internal WAO discussions combined adapted GRADE with Delphi consensus, and many recommendations rely on low or very-low certainty evidence. Public AI services summarized articles beyond their abstracts before manual review; the methods do not name the two assessors or the third resolver. The article says all conflicts were disclosed and there was no pharmaceutical influence, but provides no itemized author disclosures, so that statement is not an independent conflict audit. It cannot make one test pathway, treatment plan, or outcome universal.

2. 2

   International/Canadian: 2026 Hereditary Angioedema Guideline

   What it supports: Provides a separate GRADE-adapted pathway supporting confirmation of C1-inhibitor-deficient HAE with antigen or functional measurement, duplicate laboratory investigation after an initial result, and the boundary that normal C4 alone neither confirms nor excludes the diagnosis. It classifies every upper-airway attack as a medical emergency requiring immediate treatment and recommends emergency-department assessment even after prescribed self-treatment because specialist airway management may still be needed.

   Important limit: This 2026 update searched English-language Ovid MEDLINE publications from the prior November 2018 search through September 2024, with committee-suggested additions; its upper-airway recommendation is strong consensus supported by low-level evidence. The CHAEN/RCAOH conference received equal logistical support from HAE-treatment manufacturers BioCryst, CSL Behring, and Takeda. The authors say funders had no content or voting role and relevant conflicts triggered abstention. They also say ICMJE forms were vetted by an independent reviewer, but the main article does not name that reviewer or itemize the disclosed relationships. Jonathan Bernstein, Aleena Banerji, Michihiro Hide, and Marc Riedl also appear on the WAO guideline, so the two panels are overlapping rather than independent corroboration.

3. 3

   Journal of Allergy and Clinical Immunology: Fatal Laryngeal Attack Cohort

   What it supports: Provides the primary pedigree-based mortality evidence used by later guidance: among 728 people from 182 families, 214 had died and 70 had asphyxiated during a laryngeal attack, including 63 who were undiagnosed and seven who were diagnosed. Relatives and treating clinicians supplied detailed information for 36 fatal attacks, directly supporting recognition of laryngeal swelling as a time-critical risk.

   Important limit: This historical 2012 German pedigree cohort was partly retrospective and partly prospective. Death cases were identified from pedigrees, while details for 36 fatal attacks were reported by relatives and treating physicians, creating ascertainment, selection, and recall limitations; it does not estimate current risk under modern treatment or compare emergency strategies. The official publisher disclosure says K. Bork received consultancy fees from CSL Behring, Shire, and Viropharma; J. Hardt received research support from Stiftung Innovation; and G. Witzke declared no relevant conflicts. The accessible records do not identify study-specific funding; Hardt's disclosed research support is a relationship disclosure, not evidence that Stiftung Innovation funded this cohort. Those declared relationships require transparency but do not by themselves establish influence. The 2026 International/Canadian guideline cites this cohort directly, so it is an evidence origin rather than independent corroboration of that guideline.

4. 4

   Journal of Allergy and Clinical Immunology: 2025 Cohort Corrigendum

   What it supports: Corrects the Figure 4 description to read: Phase 2: 41 ± 49 minutes (range, 2 minutes to 4 hours). The publisher states that this correction does not affect the article's results or conclusions; it does not alter the reported cohort counts of 728 people, 182 families, 214 deaths, 70 laryngeal-asphyxiation deaths, 63 undiagnosed deaths, or seven diagnosed deaths.

   Important limit: This 2025 corrigendum, linked by PubMed as PMID 40019421, corrects presentation in the 2012 article; it is not independent replication and supplies neither a new cohort nor a contemporary risk estimate. Its narrow scope should be read alongside the original cohort's pedigree ascertainment, partly retrospective design, and reporter limitations.